Health
AstraZeneca’s Farxiga prolongs survival in chronic kidney disease trial – Clinical Trials Arena
AstraZeneca has reported positive data from a subgroup analysis from Phase III DAPA-CKD trial of Farxiga (dapagliflozin) in patients with chronic kidney disease…
AstraZeneca has reported positive data from a subgroup analysis from Phase III DAPA-CKD trial of Farxiga (dapagliflozin) in patients with chronic kidney disease (CKD).
The trial data showed that Farxiga helped reduce the composite of worsening of kidney function or risk of cardiovascular (CV) or renal death.
Farxiga is a sodium-glucose co-transporter-2 (SGLT2) inhibitor used for treating patients with insufficiently controlled type-2 diabetes (T2D).
The international, multi-centre, randomised and…
-
General6 hours agoHow the internet reacted to Brisbane Broncos winning the NRL grand final
-
General17 hours agoEnglish springer spaniels Kelly and Milo helping fight dieback in Western Australia
-
Noosa News14 hours agoMega-team of heavy horses sets world record at Good Old Days Festival
-
General16 hours agoHomicide Squad investigating ‘suspicious’ death of 84yo woman in Sydney suburb of Melonba